GoodRx (GDRX)
(Delayed Data from NSDQ)
$4.44 USD
-0.05 (-1.11%)
Updated Dec 20, 2024 04:00 PM ET
After-Market: $4.46 +0.02 (0.45%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Price, Consensus and EPS Surprise
GDRX 4.44 -0.05(-1.11%)
Will GDRX be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for GDRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GDRX
GoodRx (GDRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
GoodRx Holdings, Inc. (GDRX) Misses Q3 Earnings and Revenue Estimates
GDRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GoodRx (GDRX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Organon (OGN) Q3 Earnings and Revenues Beat Estimates
Life Time Group Holdings, Inc. (LTH) Tops Q3 Earnings and Revenue Estimates
Other News for GDRX
Truist Financial Releases a Hold Rating on GoodRx Holdings (GDRX)
TD Cowen Sticks to Its Buy Rating for GoodRx Holdings (GDRX)
GoodRx Holdings: Navigating Leadership Transition and Legislative Uncertainty
GoodRx Holdings Inc (GDRX) to Participate in J.P. Morgan Healthcare Conference
GoodRx Holdings: Buy Rating Reaffirmed Amid Leadership Stability and Growth Prospects